Click to enlarge
Buy Darzalex (daratumumab) $395.00 – $1,185.00
Back to products
Buy Kadcyla (Trastuzumab Emtansine) $1,665.00 – $2,669.00

Buy Ibrance (palbociclib)

$1,275.00 – $1,599.00

What is Ibrance (palbociclib) for?

Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.

 

How does Ibrance (palbociclib) work?

 

Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.

Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase) and the last phase, where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Palbociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)—two proteins that are involved in entering the S-phase[1].

Clear
Compare
Add to wishlist
SKU: N/A Category:
Description

Is Ibrance (palbociclib) approved?

Palbociclib was approved by:

  • Food and Drug Administration (FDA), USA:
    • February 3, 2015, for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease
    • On March 31, 2017, the accelerated approval was converted into a regular approval for use in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy
    • On April 4, 2019, the approval was expanded to include the indication for men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer when Ibrance (palbociclib) is used in combination with an aromatase inhibitor or fulvestrant .
  • European Medical Agency (EMA), European Union,  November 11, 2016

and

  • Therapeutic Goods Administration (TGA), Australia, May 3, 2017
  • Health Canada, June 5, 2018
  • Medsafe, 29 June, 2017

for use in combination with an aromatase inhibitor (e.g. letrozole) or with fulvestrant for the treatment of women with HR+/HER2- locally advanced or metastatic breast cancer who have received prior endocrine therapy.

 

How do I take Ibrance (palbociclib)?

The standard dosage is:

  • 125 mg daily for 21 consecutive days, followed by 7 days of treatment with letrozole 2.5 mg daily continuously throughout the 28-day cycle.

Complete information about palbociclib dosage and administration can be found in the resources section.

Consult your treating doctor for personalised dosing.

 

Common adverse reactions or side effects of Ibrance (palbociclib)

Most common adverse reactions with palbociclib are:

  • neutropenia
  • leukopenia
  • fatigue
  • anemia
  • infection
  • nausea
Additional information
Quantity

21 tablets of 100 mg , 21 tablets of 75 mg , 21 tablets of 125 mg , 21 capsules of 75 mg , 21 capsules of 100 mg (Limited availability) , 21 capsules of 125 mg (Limited availability)

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Ibrance (palbociclib)”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

Shipping and delivery

All orders will only be dispatched once payment has been confirmed. Please fill in the shipping details and choose the payment method that suits you best.

-Shipping costs
You should always be clearly informed of the total price of your purchase, including delivery and other associated costs.
You must explicitly agree to any additional charges, for example if the merchant offers express delivery or gift wrapping.

-Damaged goods
The merchant is responsible for any damage caused to the product, from dispatch to receipt.
If you have purchased an item that does not conform in appearance or function to the advertised product, you have the right to request that it be repaired, replaced or, if neither of these is possible, refunded.

- Non-delivery
If you have not received the product within 30 days or by the agreed date, you must notify the merchant and allow a reasonable extension of time for delivery.
For example, if the merchant informs you of a one-week delay due to problems with his suppliers, it seems reasonable to allow him this extra week. If the trader still fails to deliver despite the extension, you have the right to terminate the contract and receive a prompt refund.

Related products

Compare
Quick view
Add to wishlist

Buy Darzalex (daratumumab)

$395.00 – $1,185.00
Select options
Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma

Who is Darzalex (daratumumab) for?

Darzalex (daratumumab) is indicated for patients with:

  • newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.

  • multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.

  • multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line treatment). For this indication, it is used in combination with pomalidomide and dexamethasone.

  • multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.

Compare
Quick view
Add to wishlist

Buy Kadcyla (Trastuzumab Emtansine)

$1,665.00 – $2,669.00
Select options
Kadcyla (trastuzumab emtansine) is a cancer medicine that is used to treat advanced or metastatic HER2-positive breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane.
Compare
Quick view
Add to wishlist

Buy Keytruda (pembrolizumab)

$2,050.00
Select options
Keytruda (pembrolizumab) is a medication used for the treatment of advanced melanoma, metastatic nonsquamous NSCLC, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), recurrent classical Hodgkin Lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, solid tumours having the biomarkers MSI-H or dMMR, recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, triple-negative breast cancer.
Compare
Quick view
Add to wishlist

Buy Opdivo (Nivolumab)

$420.00 – $865.00
Select options
Opdivo (nivolumab) is a medication used for the treatment of certain types of cancer.

What is Opdivo (nivolumab) for?

Opdivo (nivolumab) is indicated for the treatment of patients with:
  • metastatic melanoma as a single agent or in combination with ipilimumab
  • metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
  • advanced renal cell carcinoma who have received prior anti-angiogenic therapy
  • classical Hodgkin lymphoma that has relapsed or progressed after other treatments
  • recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
  • locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
  • microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
  • hepatocellular carcinoma in patients who have been previously treated with sorafenib
  • for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Compare
Quick view
Add to wishlist

Buy Perjeta (Pertuzumab)

$1,470.00
Add to cart
Perjeta (pertuzumab) is a medication used for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Compare
Quick view
Add to wishlist

Buy Tecentriq (Atezolizumab)

$3,604.50
Select options
Tecentriq (atezolizumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma, for the treatment of metastatic non-small cell lung cancer (NSCLC), and for the treatment of advanced triple negative breast cancer (TNBC).
Compare
Quick view
Add to wishlist

Buy Vegzelma (Bevacizumab-adcd)

$375.00 – $1,125.00
Select options
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Vegzelma is indicated for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.